OBJECTIVES: We aimed to characterize the clinical experiences of @entity1 in whom @entity882 ( @entity882 ) complicated heparin therapy for @entity1211 ( @entity1211 ) and who switched to @entity20806 . DESIGN: A retrospective analysis of previously reported prospective, multicentre, historical-controlled @entity20806 -911 and @entity20806 -915 studies of @entity20806 therapy in @entity882 . SETTING: Inpatient. SUBJECTS: @entity1 (n = 145) administered heparin for @entity1211 and who developed @entity882 were identified. INTERVENTIONS: @entity1 were treated with @entity20806 2 mcg kg(-1) min(-1) for up to 14 days, adjusted to maintain activated partial thromboplastin times 1.5 to three times baseline. @entity1 characteristics, anticoagulation and outcomes were summarized. The primary end-point was a composite of @entity204 , amputation, or new @entity715 within 37 days of @entity20806 initiation. RESULTS: During heparin therapy, platelet counts decreased (mean +/- SD nadir: 78 +/- 67 x 10(9) L(-1)), and 75 (52%) @entity1 developed @entity715 . After heparin was discontinued, @entity1 received @entity20806 (mean dose 2.1 +/- 1.2 mcg kg(-1) min(-1)) for 6.8 +/- 4.3 days. By day 6 of @entity20806 therapy, the mean platelet count rose to >150 x 10(9) L(-1). The primary end-point occurred in 41 (28.3%) @entity1 (values of 26-44% are reported for @entity20806 therapy of @entity882 from any heparin indication). Seventeen (11.7%) @entity1 , including 12 who had also experienced @entity715 whilst on heparin, developed new @entity715 after @entity20806 initiation, typically on the day @entity20806 was discontinued or later (n = 10). Seven (4.8%) @entity1 experienced major @entity548 . CONCLUSIONS: For @entity1211 @entity1 with @entity882 , @entity20806 provides effective anticoagulation, with outcomes comparable with those reported for other @entity20806 -treated @entity882 @entity1 . New @entity715 in this setting occurred most often in @entity1 with existing @entity882 -associated @entity715 , before @entity882 recognition or either at/after @entity20806 discontinuation.

Heparin-induced @entity882 from XXXX treatment.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient'] @entity882 :: ('MESH:D013921', 'Disease') :: ['HIT', 'heparin-induced thrombocytopenia'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity20806 :: ('MESH:C031942', 'Chemical') :: ['Argatroban', 'argatroban'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']
